Literature DB >> 10918602

A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.

D H Arlt1, B Baur, B Wagner, W Höppner.   

Abstract

Multiple endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited cancer syndrome, which involves the triad of MTC, pheochromocytoma, and hyperparathyroidism. Missense mutations in one of six cysteine codons in the extracellular cysteine-rich domain of the RET proto-oncogene predispose to this disease. These mutations cause ligand-independent constitutive activation of the tyrosine kinase receptor by the formation of disulfide-bonded homodimers. We examined a different type of mutation, which results in an additional cysteine in the cysteine rich domain. A duplication of 9 bp in the first case resulted in an insertion of three amino acids between codon 633 and 634. In the second case a 12 bp duplication in exon 11 results in four additional amino acids between codon 634 and 635. Here we demonstrate that an additional cysteine causes a ligand independent dimerization of the RET receptor in transfected NIH3T3 cells, which results in an activation of the intracellular tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918602     DOI: 10.1038/sj.onc.1203688

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.

Authors:  Wolfgang Gartner; Ivelina Mineva; Teodora Daneva; Sabina Baumgartner-Parzer; Bruno Niederle; Heinrich Vierhapper; Michael Weissel; Ludwig Wagner
Journal:  Hum Genet       Date:  2005-04-20       Impact factor: 4.132

2.  Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.

Authors:  Haijiao Zhang; Sophie Means; Anna Reister Schultz; Kevin Watanabe-Smith; Bruno C Medeiros; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Tim Kükenshöner; Oliver Hantschel; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2017-06-26       Impact factor: 12.701

Review 3.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

4.  Plot protein: visualization of mutations.

Authors:  Tychele Turner
Journal:  J Clin Bioinforma       Date:  2013-07-22

5.  Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.

Authors:  Carman K M Ip; Patrick K S Ng; Kang Jin Jeong; S H Shao; Zhenlin Ju; P G Leonard; Xu Hua; Christopher P Vellano; Richard Woessner; Nidhi Sahni; Kenneth L Scott; Gordon B Mills
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.